STING1 and neoplasm: Recently, a promising and popular approach has been developed to trigger innate immunity and drive anti-tumor adaptive immunity by activating the cyclic guanosine monophosphate-adenosine monophosphate (GMP-AMP) synthase-stimulator of interferon genes (cGAS-STING) signaling pathway and releasing type I interferons (IFNs) [9].